Cost-effectiveness analysis: Stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists

Value in Health

Volumn 16, Issue 1, 2013, Pages 14-22

  Barkun, Alan N ^a,b   Adam, Viviane ^a   Martel, Myriam ^a   Marc, Bardou ^c,d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

cost effectiveness; H2RA; proton pump inhibitors; stress ulcer bleeding

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ACUTE RESPIRATORY FAILURE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HYPOVOLEMIC SHOCK; INTENSIVE CARE; LENGTH OF STAY; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEPSIS; SEPTICEMIA; SHOCK; STRESS ULCER;

ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DECISION TREES; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COSTS; HISTAMINE H2 ANTAGONISTS; HUMANS; LENGTH OF STAY; MULTIVARIATE ANALYSIS; PEPTIC ULCER; PROTON PUMP INHIBITORS; UNITED STATES;

EID: 84872692223     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.08.2213     Document Type: Article

References (68)

1. M.J. Spirt Stress-related mucosal disease: risk factors and prophylactic therapy Clin Ther 26 2004 197 213
2. N. Stollman, and D.C. Metz Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients J Crit Care 20 2005 35 45
3. L. Laine, S.P. Curtis, and M. Langman Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac Gastroenterology 135 2008 1517 1525
4. E.J. Kuipers, J.J. Sung, and A. Barkun Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding Adv Ther 28 2011 150 159
5. S. Pongprasobchai, S. Kridkratoke, and C. Nopmaneejumruslers Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis J Med Assoc Thai 92 2009 632 637
6. P.C. Lin, C.H. Chang, and P.I. Hsu The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis Crit Care Med 38 2010 1197 1205
7. Nationwide Inpatient Sample 2008. Healthcare cost and utilization project. Available from: http://www.hcup-us.ahrq.gov/databases.jsp. [Accessed March 1, 2011].
8. L. Somberg, J. Morris Jr, and R. Fantus Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease J Trauma 64 2008 1202 1210
9. Solouki M, Marashian SM, Kouchak M, Mokhtari M, Nasiri E. Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos 2009;8:37-42.
10. H. Powell, M. Morgan, S.K. Li, and J.H. Baron Inhibition of gastric acid secretion in the intensive care unit after coronary artery bypass graft: a pilot control study of intravenous omeprazole by bolus and infusion, ranitidine and placebo Theor Surg 8 1993 125 130
11. J.O. Phillips, M.H. Metzler, R.E. Huckfeldt, and K. Olsen A multicenter, prospective, randomized clinical trial of continuous I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcer prophylaxis [abstract] Crit Care Med 26 1998 A101
12. X.Z.W. Pan, Z. Li, and G. Xu The preventive effects of rabeprazole on upper gastrointestinal tract hemorrhage in patients with severe acute pancreatitis Chinese J Gastroenterol 9 2004 PP30 PP32
13. J. Morris, R. Karlstadt, D. Blatcher, and D. Field Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH≥4.0 compared with continuous infusion H2-receptor antagonist in intensive care unit patients Crit Care Med 29 2001 A147
14. M.J. Levy, C.B. Seelig, N.J. Robinson, and J.E. Ranney Comparison of omeprazole and ranitidine for stress ulcer prophylaxis Dig Dis Sci 42 1997 1255 1259
15. I. Kantorova, P. Svoboda, and P. Scheer Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial Hepatogastroenterology 51 2004 757 761
16. M. Hata, M. Shiono, and H. Sekino Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery Circ J 69 2005 331 334
17. M. Fink, R. Karlstadt, R. Maroko, and B. Field Intravenous pantoprazole and continuous infusion cimetidine prevent upper gastrointestinal bleeding regardless of APACHE II score in high risk intensive care unit patients. Gastroenterology 124 2003 A625
18. J.R. De Azevedo, M.G. Soares, G.A.E. Silva, and G. De Lima Palacio Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs. GED - Gastrenterologia Endoscopia Digestiva 19 2000 239 244
19. S.A. Conrad, A. Gabrielli, and B. Margolis Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients Crit Care Med 33 2005 760 765
20. Clinical Trials.gov. U.S. National Institute of Health. Available from: www.clinicaltrials.gov. [Accessed April 1, 2011].
21. K. Dickersin, R. Scherer, and C. Lefebvre Identifying relevant studies for systematic reviews BMJ 309 1994 1286 1291
22. G.M. Brophy, M.L. Brackbill, K.L. Bidwell, and D.F. Brophy Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients Neurocrit Care 13 2010 176 181
23. A.N. Barkun, M. Bardou, C.Q. Pham, and M. Martel Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis Am J Gastroenterol 107 2012 507 520
24. V. Adam, and A.N. Barkun Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States Value Health 11 2008 1 3
25. U.S. Bureau of Labor Statistics. Available from: http://www.bls.gov/. [Accessed March 1, 2011].
26. T. Tarn Pharmacoeconomic guidelines around the world ISPOR CONNECTIONS 10 2004 5 15
27. Academy of Managed Care Pharmacy (AMCP). Sullivan SD, Avey SG, Flynn JA, Lee J, Lee TA, Luce BR, McElwee N, Malone D, Neumann PJ, Penna P, Sherman H, Watkins J, Fry RN. A Format for Submission of Clinical and Economic Evidence of Pharmaceuticals in Support of Formulary Consideration. Foundation for Managed Care Pharmacy, Academy of Managed Care Pharmacy, 2009.
28. National Institute for Health and Clinical Excellence. Single Technology appraisal. Specifications for manufacturer/sponsor submission of evidence. London: National Institute for Health and Clinical Excellence, 2009.
29. Amin M, Brady B, Brown A, Lee K, McGahan L, Mensinkai S, Cheng M, Coyle D, Hoch J, Marshall D, O Brien B. Guidelines for the Economic Evaluation of Health Technologies (3rd ed.). Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health, 2006.
30. E. Fenwick, and S. Byford A guide to cost-effectiveness acceptability curves Br J Psychiatry 187 2005 106 108
31. K.N. Schupp, L.M. Schrand, and A.H. Mutnick A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother 37 2003 631 635
32. D. Cook, G. Guyatt, and J. Marshall A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation Canadian Critical Care Trials Group. N Engl J Med 338 1998 791 797
33. D. Cook, D. Heyland, and L. Griffith Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation Canadian Critical Care Trials Group. Crit Care Med 27 1999 2812 2817
34. G.M. Mutlu, E.A. Mutlu, and P. Factor GI complications in patients receiving mechanical ventilation Chest 119 2001 1222 1241
35. M.S. Phillips Clinical research: ASHP guidelines and future directions for pharmacists Am J Health Syst Pharm 56 1999 344 346
36. D.J. Cook, H.D. Fuller, and G.H. Guyatt Risk factors for gastrointestinal bleeding in critically ill patients Canadian Critical Care Trials Group. N Engl J Med 330 1994 377 381
37. P. Marik, T. Vasu, A. Hirani, and M. Pachinburavan Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis Crit Care Med 38 2010 2222 2228
38. Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs histamine 2 receptor antagonists for stress-related mucosal bleeeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol 2012;107:507-20.
39. R.A. Enns, Y.M. Gagnon, K.P. Rioux, and A.R. Levy Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding Aliment Pharmacol Ther 17 2003 225 233
40. Y.M. Gagnon, A.R. Levy, and M.A. Eloubeidi Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding Value Health 6 2003 457 465
41. B.M. Spiegel, J.J. Ofman, K. Woods, and N.B. Vakil Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies Am J Gastroenterol 98 2003 86 97
42. G.I. Leontiadis, A. Sreedharan, and S. Dorward Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 11 iii-iv 2007 1 164
43. P. Barton, S. Bryan, and S. Robinson Modelling in the economic evaluation of health care: selecting the appropriate approach J Health Serv Res Policy 9 2004 110 118
44. J.M. Inadomi Decision analysis and economic modelling: a primer Eur J Gastroenterol Hepatol 16 2004 535 542
45. S. Al-Sabah, A.N. Barkun, and K. Herba Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding Clin Gastroenterol Hepatol 6 2008 418 425
46. A.N. Barkun, V. Adam, and J.J. Sung Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding Pharmacoeconomics 28 2010 217 230
47. A.N. Barkun, K. Herba, and V. Adam The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding Aliment Pharmacol Ther 20 2004 195 202
48. A.N. Barkun, K. Herba, and V. Adam High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis Aliment Pharmacol Ther 19 2004 591 600
49. M.V. Bala, and G.A. Zarkin Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ 9 2000 177 180
50. Barkun AN, Adam V, Martel M, Bardou M. Stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists or sucralfate: a cost-effectiveness analysis. In: ISPOR 14th Annual European Congress. Madrid, Spain, 2011.
51. T. Ben-Menachem, R. Fogel, and R.V. Patel Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit: a randomized, controlled, single-blind study Ann Intern Med 121 1994 568 575
52. V. Darlong, T.S. Jayalakhsmi, H.L. Kaul, and R. Tandon Stress ulcer prophylaxis in patients on ventilator Trop Gastroenterol 24 2003 124 128
53. J.M. Eddleston, A. Vohra, and P. Scott A comparison of the frequency of stress ulceration and secondary pneumonia in sucralfate- or ranitidine-treated intensive care unit patients Crit Care Med 19 1991 1491 1496
54. J.M. Grau, J. Casademont, and J. Fernandez-Sola Prophylaxis of gastrointestinal tract bleeding in patients admitted to a general hospital ward: comparative study of sucralfate and cimetidine Scand J Gastroenterol 28 1993 244 248
55. I. Kappstein, G. Schulgen, and T. Friedrich Incidence of pneumonia in mechanically ventilated patients treated with sucralfate or cimetidine as prophylaxis for stress bleeding: bacterial colonization of the stomach Am J Med 91 1991 125S 131S
56. U.K. Misra, J. Kalita, and S. Pandey A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage J Neurol Sci 239 2005 5 10
57. K.K. Pickworth, R.E. Falcone, J.E. Hoogeboom, and S.A. Santanello Occurrence of nosocomial pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and ranitidine Crit Care Med 21 1993 1856 1862
58. S. Prakash, A. Rai, A. Gogia, and S. Prakash Nosocomial pneumonia in mechanically ventilated patients receiving ranitidine or sucralfate as stress ulcer prophylaxis [clinical investigation] Ind J Anaesth 52 2008 179
59. G. Prod'hom, P. Leuenberger, and J. Koerfer Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer: a randomized controlled trial Ann Intern Med 120 1994 653 662
60. P. Ryan, J. Dawson, and D. Teres Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate Arch Surg 128 1993 1353 1357
61. M.H. Thomason, E.S. Payseur, and A.M. Hakenewerth Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine J Trauma-Inj Infect Crit Care 41 1996 503 508
62. C.S. Eom, C.Y. Jeon, and J.W. Lim Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis CMAJ 183 2011 310 319
63. H.G. Eichler, S.X. Kong, and W.C. Gerth Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7 2004 518 528
64. D. Gyrd-Hansen Willingness to pay for a QALY Health Econ 12 2003 1049 1060
65. A. Maetzel Cost-effectiveness analysis: out of touch with clinical reality? Arthritis Rheum 53 2005 3 4
66. M.E. Sartore, and K.M. Kamal Costs and thresholds in cost-effectiveness analysis Aliment Pharmacol Ther 26 2007 1455 1456
67. P.A. Ubel, R.A. Hirth, M.E. Chernew, and A.M. Fendrick What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 2003 1637 1641
68. A.H. Briggs, R. Goeree, G. Blackhouse, and B.J. O'Brien Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease Med Decis Making 22 2002 290 308